MY ACCOUNT | NEWSLETTER |

Intravitreal gentamicin injection for the treatment of end-stage glaucoma in rabbits


Glaucoma is a painful and blinding condition that occurs in many species, including rabbits. When medication is no longer effective in maintaining intraocular pressure (IOP), enucleation is the recognized treatment for rabbits with end-stage glaucoma. However, this procedure carries risks relating to the procedure and the anesthesia.

The aim of this retrospective study was to report the efficacy of intravitreal gentamicin injection in controlling IOP in blind eyes of rabbits with end-stage glaucoma. Researchers retrospectively assessed ocular and non-ocular complications.

Medical record review was performed to identify five client-owned rabbits (eight eyes) that were treated by intravitreal injection of 6-20 mg of gentamicin per eye (median 7.18 mg/kg) for chronic, end-stage glaucoma. 

Treatment was unilateral in two and bilateral in three rabbits. Researchers assessed IOP control via rebound tonometry readings performed approximately two weeks, one month, three months, and six months after injection. Total follow-up was between 313 and 1,111 days. Ocular complications were recorded, and systemic health was estimated by the owner-answered questionnaire and changes in body weight.

IOP was <25 mmHg in 87.5% of eyes 3 months post-injection. The most common ocular complications were cataracts (62.5%), anterior uveitis (25%), retinal detachment (12.5%), and corneal erosion (12.5%). There were no behavioral or body weight changes suggestive of systemic complications.

In conclusion, 87.5% of rabbit eyes treated with intravitreal gentamicin had controlled IOP 3 months after injection. All eyes were blind at the time of injection. Ocular side effects were common. Investigation of the safety and systemic effects of intravitreal gentamicin injection is required. However, the research team did not identify any overt complications in treated rabbits in this study.

Gemma Turner, et al. “Clinical outcome of intravitreal gentamicin injection for the treatment of end-stage glaucoma in five rabbits (eight eyes).” Open Vet J. 2022 Nov-Dec;12(6):822-829. doi: 10.5455/OVJ.2022.v12.i6.6.

Like0
Dislike0
  • Please enter a comment


Name *
Email address *
Comment *


* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.


I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies



More news

Ethical issues in geriatric feline medicine

Like0
Dislike0

The future of canine glaucoma therapy

Like0
Dislike0

Impact of antibiotic use in the swine industry

Like0
Dislike0

WSU researchers join $9.6M push to fight Rift Valley fever

Like0
Dislike0

PetPace™ Launches World's First AI Smart Collar that Includes 24/7 Global Telehealth and Telemedicine—Revolutionizing Real-Time Health Monitoring for Dogs and Cats

Like0
Dislike0

Newsletter

 
 

News of interest

EVENTS

Copyright © 2025 - All Rights Reserved
ISSN 2768-198X

Top